Evanston Investments Inc. dba Evanston Advisors increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 30.8% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 102,783 shares of the biopharmaceutical company’s stock after buying an additional 24,190 shares during the period. Evanston Investments Inc. dba Evanston Advisors’ holdings in Gilead Sciences were worth $6,981,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of GILD. Capital International Ltd. CA raised its stake in shares of Gilead Sciences by 17.0% in the fourth quarter. Capital International Ltd. CA now owns 165,007 shares of the biopharmaceutical company’s stock valued at $11,816,000 after buying an additional 24,000 shares during the last quarter. Princeton Portfolio Strategies Group LLC raised its position in shares of Gilead Sciences by 18.1% in the fourth quarter. Princeton Portfolio Strategies Group LLC now owns 19,933 shares of the biopharmaceutical company’s stock valued at $1,427,000 after buying an additional 3,060 shares during the last quarter. Horizon Kinetics LLC raised its position in shares of Gilead Sciences by 12.6% in the fourth quarter. Horizon Kinetics LLC now owns 13,000 shares of the biopharmaceutical company’s stock valued at $930,000 after buying an additional 1,450 shares during the last quarter. Denver Investment Advisors LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at about $462,000. Finally, Ladenburg Thalmann Financial Services Inc. raised its position in Gilead Sciences by 8.9% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 173,086 shares of the biopharmaceutical company’s stock worth $12,514,000 after buying an additional 14,150 shares in the last quarter. 74.02% of the stock is owned by institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down 0.32% during midday trading on Friday, reaching $72.11. The company’s stock had a trading volume of 6,052,601 shares. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $82.10. The firm has a market capitalization of $94.17 billion, a P/E ratio of 7.83 and a beta of 1.21. The stock has a 50-day moving average of $72.61 and a 200 day moving average of $68.83.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.08 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.88%. Gilead Sciences’s dividend payout ratio is currently 22.58%.
WARNING: “Gilead Sciences, Inc. (GILD) Position Increased by Evanston Investments Inc. dba Evanston Advisors” was originally published by BNB Daily and is the property of of BNB Daily. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/19/evanston-investments-inc-dba-evanston-advisors-acquires-24190-shares-of-gilead-sciences-inc-gild-updated-updated.html.
A number of research analysts have recently weighed in on GILD shares. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 21st. Piper Jaffray Companies restated a “buy” rating on shares of Gilead Sciences in a report on Friday, April 21st. Barclays PLC reaffirmed an “overweight” rating and set a $85.00 price target (down from $90.00) on shares of Gilead Sciences in a research report on Sunday, April 23rd. Stifel Nicolaus reaffirmed a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Monday, April 24th. Finally, Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 target price for the company. in a research report on Tuesday, April 25th. Twelve analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $80.31.
In related news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the sale, the executive vice president now owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. Insiders have sold 206,666 shares of company stock valued at $15,223,184 in the last three months. Corporate insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.